Upstream Bio, Inc. (UPB)
7.18
+0.57
(+8.62%)
USD |
NASDAQ |
Aug 25, 16:00
7.18
0.00 (0.00%)
Pre-Market: 19:59
Upstream Bio Net Income (Quarterly) : -39.70M for June 30, 2026
Net Income (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -39.70M |
| March 31, 2026 | -40.59M |
| December 31, 2025 | -42.46M |
| September 30, 2025 | -33.75M |
| Date | Value |
|---|---|
| June 30, 2025 | -39.97M |
| March 31, 2025 | -27.27M |
| December 31, 2024 | -21.24M |
| September 30, 2024 | -15.99M |
Net Income Definition
Represents net income for the period and date(s) requested in local currency by default.
Net Income (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Net Income (Quarterly) Benchmarks
| Sutro Biopharma, Inc. | -38.53M |
| Compass Therapeutics, Inc. | -25.15M |
| ACADIA Pharmaceuticals, Inc. | 31.50M |
| Alnylam Pharmaceuticals, Inc. | 164.49M |
| Anika Therapeutics, Inc. | 3.309M |
Net Income (Quarterly) Related Metrics
| Revenue (Quarterly) | 0.773M |
| Total Expenses (Quarterly) | 40.48M |
| EPS Diluted (Quarterly) | -0.7276 |
| Enterprise Value | 132.90M |
| Gross Profit Margin (Quarterly) | 93.53% |
| Profit Margin (Quarterly) | -5.14K% |
| Earnings Yield | -40.20% |
| Normalized Earnings Yield | -40.16 |